Cancer Pain Market to Exhibit Rapid Growth Rate | Sorrento Therapeutics, WEX Pharmaceuticals, Tetra Bio-pharma, Kyowa Kirin Co, Grünenthal GmbH, Jazz Pharmaceuticals, companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

{Delhi, India} To strategically aid Cancer Pain companies developing drugs for Cancer Pain, DelveInsight launched a report titled as “Cancer Pain Market Insight, Epidemiology And Market Forecast - 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of the Cancer Pain market.

Get a free sample of “Cancer Pain Market Insight Report”: 

Key Highlights from Cancer Pain market Report:

• The Cancer Pain market size was valued approximately USD 1,600 million in 2021 and is expected to grow with a significant CAGR during the study period (2019-2032)
• In 2021, the reported new instances of breakthrough cancer pain amounted to approximately 1,392,000 cases in the United States.
• Key Cancer Pain Companies: Sorrento Therapeutics, WEX Pharmaceuticals, Tetra Bio-pharma, Kyowa Kirin Co., Ltd., Archimedes Development Ltd, Endo Pharmaceuticals, Grünenthal GmbH, Jazz Pharmaceuticals, Janssen Research, Taiwan Mundipharma Pharma, Tris Pharma, Inc., INSYS Therapeutics Inc, and others
• Key Cancer Pain Therapies: Resiniferatoxin, Tetrodotoxin, QIXLEEF, KW-2246, Fentanyl citrate, Oxymorphone ER, Tapentadol Extended Release, Sativex, JNJ-42160443, Oxycodone, Cebranopadol, Fentanyl sublingual spray, and others
• The Cancer Pain epidemiology based on gender analyzed that Cancer pain affects males and female equally
• The Cancer Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Pain pipeline products will significantly revolutionize the Cancer Pain market dynamics.

Cancer Pain Country based Treatment Overview: 

The Cancer Pain Treatment section delineates the specifics of traditional and contemporary medical interventions accessible within the Cancer Pain market to address this condition. Additionally, it furnishes Cancer Pain treatment protocols and recommendations followed in the United States, Europe, and Japan.

Cancer pain refers to any discomfort or discomfort experienced by individuals diagnosed with cancer. It can manifest as acute or chronic pain and might result from the cancer itself, the treatments undergone (such as surgery, chemotherapy, or radiation), or other complications associated with the disease.

To Know in detail about the Cancer Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Pain Market Forecast

Cancer Pain Epidemiology Insights: 

The report includes epidemiological data presenting both historical and projected figures, categorized into various segments such as Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incident Cases of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, and Incident Cases of Breakthrough Cancer Pain (BTcP).

• In 2021, approximately 2,321,000 new cases of cancer-related pain were reported in the US. It is projected that these numbers will rise by the year 2032.
• In 2021, around 2,278,000 cases of cancer-related pain were recorded across the EU4 countries and the UK. It is projected that these figures will see an increase by the year 2032.
• In 2021, Germany reported the highest number of cancer-related pain cases among the EU4 countries, totaling around 634,000 cases. It is projected that these numbers will see an increase by the year 2032.

Cancer Pain Epidemiology Segmentation:

The Cancer Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into

• Total Prevalence of Cancer Pain
• Prevalent Cases of Cancer Pain by severity
• Gender-specific Prevalence of Cancer Pain
• Diagnosed Cases of Episodic and Chronic Cancer Pain

Download the report to understand which factors are driving Cancer Pain epidemiology trends @ Cancer Pain Epidemiology Forecast

Cancer Pain Therapies and Key Companies

• Resiniferatoxin: Sorrento Therapeutics
• Tetrodotoxin: WEX Pharmaceuticals
• QIXLEEF: Tetra Bio-pharma
• KW-2246: Kyowa Kirin Co., Ltd.
• Fentanyl citrate: Archimedes Development Ltd
• Oxymorphone ER: Endo Pharmaceuticals
• Tapentadol Extended Release: Grünenthal GmbH
• Sativex: Jazz Pharmaceuticals
• JNJ-42160443: Janssen Research
• Oxycodone: Taiwan Mundipharma Pharma
• Cebranopadol: Tris Pharma, Inc.
• Fentanyl sublingual spray: INSYS Therapeutics Inc

Emerging Cancer Pain drugs Uptake:

This section concentrates on the adoption rate of newly introduced or anticipated drugs in the cancer pain market from 2019 to 2032. The assessment includes the uptake of these drugs within the market, patient acceptance of various therapies, and the sales performance of each drug in relation to treating cancer-related pain.

The present market expects the arrival of specific products: Resiniferatoxin from Sorrento Therapeutics, Tetrodotoxin from WEX Pharmaceuticals, and QIXLEEF by Tetra BioPharma.

Discover more about therapies set to grab major Cancer Pain market share @ Cancer Pain Treatment Landscape 

Cancer Pain Market Forecast:

Opioid-based therapies remain the primary approach for managing moderate-to-severe pain associated with cancer. The objective of extended opioid treatment is to deliver consistent, meaningful relief from pain while minimizing side effects and enhancing the overall quality of life. Generally, pure μ-agonist opioids are preferred for treating cancer-related pain. However, certain opioids like pethidine and dextropropoxyphene are discouraged due to their potential for causing adverse effects.

The Cancer Pain Market Drivers Include - The increasing prevalence of cancer cases worldwide and the rise in awareness regarding cancer-associated pain being experienced by patients will drive the overall cancer pain therapeutics market in the upcoming years, Opioids are necessary for the majority of cancer patients, but serious side effects and addiction-related concerns are associated with it. With the expected launch of drugs like tetrodotoxin and resiniferatoxin, the market will experience a major shift toward these nonopioid-based medications for treating cancer pain.

Scope of the Cancer Pain Market Report:

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Cancer Pain Market Size: ~1,600 million in 2021
• Key Cancer Pain Companies: Sorrento Therapeutics, WEX Pharmaceuticals, Tetra Bio-pharma, Kyowa Kirin Co., Ltd., Archimedes Development Ltd, Endo Pharmaceuticals, Grünenthal GmbH, Jazz Pharmaceuticals, ansd oh

To know more about Cancer Pain companies working in the treatment market, visit @ Cancer Pain Clinical Trials and Therapeutic Assessment

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Cancer Pain market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the Cancer Pain market, including the competitive environment, key companies developing drugs for Cancer Pain, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the Cancer Pain market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Cancer Pain. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Cancer Pain market with clarity and purpose. 

Related Reports:

Cancer Pain Epidemiology 

DelveInsight's 'Cancer Pain Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cancer Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.  

Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study!

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

Contact No.: +91-9650213330

City: 304 S. Jones Blvd #2432,

State:  Las Vegas NV 89107

Country: United States

Website: https://www.delveinsight.com/consulting